Ospedale Senatore Antonio Perrino
Welcome,         Profile    Billing    Logout  
 19 Trials 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Daniele, Gennaro
MANGO-2, NCT01706120 / 2012-003043-29: Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Active, not recruiting
4
400
Europe
Bevacizumab, Avastin, Paclitaxel, Carboplatin
National Cancer Institute, Naples, Mario Negri Institute for Pharmacological Research
Ovarian Cancer
12/24
12/24
ENGOT-ov 17, NCT01802749 / 2012-004362-17: Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer

Active, not recruiting
3
406
Europe, RoW
Bevacizumab, Avastin, Paclitaxel, Carboplatin, pegylated liposomal doxorubicin, Caelyx, Gemcitabine
National Cancer Institute, Naples, Mario Negri Institute for Pharmacological Research
Recurrent Ovarian Cancer
12/23
12/23
MITO END-3, NCT03503786 / 2016-004403-31: Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer

Active, not recruiting
2
125
Europe
Carboplatin, Paclitaxel, Avelumab
National Cancer Institute, Naples, Pfizer s.r.l.
Endometrial Cancer
12/23
12/23
MANGO OV4, NCT03410784 / 2016-003926-18: Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Recruiting
2
72
Europe
Pembrolizumab, Paclitaxel, Carboplatin
National Cancer Institute, Naples, Mario Negri Institute for Pharmacological Research
Ovarian Cancer
08/24
12/24
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Active, not recruiting
1/2
61
Europe, Japan, US, RoW
M1774, Tuvusertib, Cemiplimab
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Non-Small Cell Lung Cancer
06/24
03/25
ELVN-002-003, NCT06328738: ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Recruiting
1
255
Europe, US, RoW
ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin
Enliven Therapeutics
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
01/27
07/28
NCT06586515: A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting
1
530
Europe, Canada, Japan, US
LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil
Eli Lilly and Company, Loxo Oncology, Inc.
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
03/29
03/29
NCT06551142: A Study of GSK5764227 in Participants With Advanced Solid Tumors

Recruiting
1
240
Canada, Japan, US, RoW
GSK5764227, Topotecan
GlaxoSmithKline
Neoplasms
07/26
03/27
SGNTGT-001, NCT04254107: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Terminated
1
132
Europe, Canada, US
SEA-TGT, SGN-TGT, sasanlimab, brentuximab vedotin, Adcetris
Seagen Inc.
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
12/23
12/23
ELVN-002-001, NCT05650879: ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Recruiting
1
198
Europe, US, RoW
ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1
Enliven Therapeutics
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
07/26
07/26
Morabito, Alessandro
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruiting
3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
04/25
10/25
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
NCT00997009 / 2009-010099-74: Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Active, not recruiting
2
108
Europe
paclitaxel, carboplatin, cetuximab
National Cancer Institute, Naples
Cervical Cancer
12/24
12/24
BEAT, NCT03896074 / 2018-003973-82: Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients

Not yet recruiting
2
206
Europe
Atezolizumab, Bevacizumab
Fondazione Ricerca Traslazionale
Non-small-cell Lung Cancer Patients
05/22
04/23
MP-LALC, NCT03379441: Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC

Not yet recruiting
2
126
Europe
Pembrolizumab Injectable Product
University of Turin, Italy
Non Small Cell Lung Cancer Patients
01/23
01/23
MILES-5, NCT03975114: A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC

Recruiting
2
460
Europe
Chemotherapy, Durvalumab, Tremelimumab
National Cancer Institute, Naples, University of Campania "Luigi Vanvitelli", AstraZeneca
Carcinoma, Non-Small-Cell Lung
12/23
06/24
CAPLAND, NCT04811001 / 2019-002869-35: Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

Recruiting
2
170
Europe
Osimertinib, Tagrisso, Dacomitinib, Vizimpro
Fondazione Ricerca Traslazionale, Pfizer srl
NSCLC
12/23
12/23
ZIDON, NCT00996983 / 2008-005307-26: Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer

Active, not recruiting
2
16
Europe
ziconotide
National Cancer Institute, Naples
Pain, Neuropathic Pain, Intractable Pain, Cancer
12/24
12/24
THOR, NCT05623319: Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)

Recruiting
2
60
Europe
Pembrolizumab/Olaparib
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Merck Sharp & Dohme LLC
SCLC,Extensive Stage
08/26
08/26
NCT04416672: Validation of the Italian Version of the PRO-CTCAE

Recruiting
N/A
3675
Europe
PRO-CTCAE items
National Cancer Institute, Naples
Malignant Neoplasms
07/24
07/24
MITO-12, NCT01061619: Pathway to Diagnosis of Ovarian Cancer

Active, not recruiting
N/A
400
Europe
National Cancer Institute, Naples
Ovarian Cancer
11/24
11/24
I-STOP, NCT05418660: Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

Recruiting
N/A
300
Europe
Immunotherapy, Nivolumab, Pembrolizumab, Atezolizumab
University of Milano Bicocca, Azienda Ospedaliera San Gerardo di Monza
Non-small Cell Lung Cancer
11/24
11/24
PETRA, NCT02035683: PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy

Active, not recruiting
N/A
220
Europe
PET/CT
National Cancer Institute, Naples
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
12/24
12/24

Download Options